SCYX heads into its May 13 earnings report having lost nearly a fifth of its value in a single month, with the stock now trading below $1.
The most striking feature of the run-up is the divergence between a falling price and a surprisingly composed lending market. Short interest at 3.1% of the free float is modest and has actually retreated about 12% over the past week — meaning short sellers have been pulling back, not pressing their advantage, even as the stock slides. Cost to borrow is also unremarkable at 1.2% APR, having shed more than 40% over the same period. Borrow availability has loosened materially too: utilization briefly touched 97% on May 4 — the tightest the lending pool has been all year — but quickly eased back to 42% within days. That spike and reversal looks more like a positioning flush than the start of a sustained squeeze. The options market adds little directional signal; the put/call ratio is negligible and essentially unchanged for weeks, suggesting there is no meaningful hedging pressure ahead of the print.
What this means is that the 17.6% one-month decline is being driven by something other than a crowded short trade or options-market fear. Bulls point to the commercial reality of Brexafemme (ibrexafungerp), SCYNEXIS's FDA-approved antifungal, as a long-duration asset in a market with limited competition. The company's EPS surprise factor ranks near the 90th percentile historically — it has consistently beaten low expectations. Bears focus on cash burn: the income statement shows a net loss of roughly $26.7 million against revenue of just $1.2 million on an estimated basis, with the path to profitability still undefined. The ORTEX total stock score of 69 is solid, driven by a momentum component that has held in the high-70s despite the recent price weakness — a signal that relative performance across the universe remains better than the stock's own chart suggests.
The CEO, David Angulo, bought 108,695 shares at $0.92 on April 1 — a $100,000 commitment at a price just above where the stock now trades. That follows a pattern of open-market purchases at progressively lower prices stretching back to 2024. The signal is consistent but modest in dollar terms, reflecting the company's micro-cap reality rather than a high-conviction institutional-scale bet.
Tomorrow's print will test whether the commercial ramp in Brexafemme is accelerating fast enough to narrow the cash-consumption story to a level the market is willing to finance.
See the live data behind this article on ORTEX.
Open SCYX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
